Back to resultsThe Intervention of Psychobiotics in Patients With Anxiety Disorders
Primary Purpose
Anxiety Disorders
Status
Recruiting
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Heat-treated PS23
Placebo
Sponsored by
About this trial
This is an interventional supportive care trial for Anxiety Disorders focused on measuring anxiety, microbiota, psychobiotics
Eligibility Criteria
Inclusion Criteria: Age 20~65 years old Patients perceived that they had anxiety-related complaints, or with any type of anxiety disorders of adjustment disorders referred from the Departments of Psychiatry, Neurology, Internal Medicine, and Family Medicine in Mackay Memorial Hospital. Adult GAD-7 ≥ 8 points (to screen for generalized anxiety disorder) or a DSM-5 diagnosis of generalized anxiety disorder (F41.1) or unspecified anxiety disorder (F41.9) Those who are currently under the treatment of selective serotonin reuptake inhibitors (SSRI) will only be included if their SSRI treatment has been stable or has not been changed for 4 weeks. Exclusion Criteria: Have taken antibiotics or are receiving antibiotic treatment within one month. Have used probiotic products in powder, capsule or tablet form within two weeks (excluding yogurt, Yakult and other related foods). Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy). Past or current patients with inflammatory bowel disease. Those with a history of cancer. Those who are allergic to lactic acid bacteria products. Patients with severe depression (Patient Health Questionnaire-9 (PHQ-9) ≧ 20 points), or possible neurocognitive impairments (Mini-Mental States Examination (MMSE)<20), or those that had suicidal ideation noted on item 9 from PHQ-9. Patients with chronic psychiatric diseases who are currently taking drugs to treat acute diseases, organic brain diseases, or newly diagnosed or changed drugs within three months. Those who are receiving parenteral nutrition. Those who are evaluated by the principal investigator to be unsuitable to participate in the research.
Sites / Locations
- Mackay Memorial HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Heat-treated PS23
Placebo
Arm Description
Lactobacillus paracasei PS23 heat-treated
microcrystalline cellulose
Outcomes
Primary Outcome Measures
Changes from the HAM-A compared to placebo.
Hamilton Anxiety Scale(HAM-A) score changes downwards ≥ 20% indicate significant improvement.
Secondary Outcome Measures
Differences in the Generalized Anxiety Disorder 7-item (GAD-7) compared to placebo.
The GAD-7 is a easy to perform initial screening tool for generalized anxiety disorder, When screening for anxiety disorders, a score of 8 or greater represents a reasonable cut-point for identifying probable cases of generalized anxiety disorder;Using a cut-off of 8 the GAD-7 has a sensitivity of 92% and specificity of 76% for diagnosis generalized anxiety disorder.
Differences in the State and Trait Anxiety Index (STAI) compared to placebo.
The STAI measures levels of anxiety in the current 'state' or from the 'trait'. Good reliability (0.86~0.95) and sensitivity (0.85) were found and the higher the scores, the severe the levels of anxiety.
Differences in Insomnia Severity index (ISI) compared to placebo.
The ISI is a brief instrument that was designed to assess the severity of both nighttime and daytime components of insomnia.
Differences in The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 (QLESQ-16) compared to placebo.
The QLESQ-16 is a valid, reliable self-report instrument for assessing quality of life.
Differences in the The Profile of Mood States (POMS) compared to placebo.
The POMS is a psychological rating scale used to assess transient, distinct mood states.
Differences in Visual Analogue Scale-GI (VAS-GI) compared to placebo.
VAS consists of a line, 10 cm in length. Individuals point to or mark a spot on the line where they feel indicates their current their emotion, fatigue level and sleep quality. The score of emotion level is from 0cm (very nervous) to 10 cm (very relaxing). The score of fatigue level is from 0 cm (very energetic) to 10 cm (very sleepy). The score of sleep quality is from 0 cm (poor) to 10 cm (sleep well). The maximum total score is 100% (equal 10cm).
Changes in blood TAC (Total Antioxidant Capacity) before and after consumption of probiotics
TAC is the biomarker for Oxidative stress.
Changes in blood DHEA-S (Dehydroepiandrosterone sulfate) compared to placebo.
DHEA-S is the biomarker for anti-aging，among the neuroactive steroids, dehydroepiandrosterone (3b-hydroxyandrost-5-ene-17-one, [DHEA]) and its sulfated metabolite DHEA sulfate (DHEAS) have been shown to be potent modulators of neural function, including neurogenesis, neuronal growth and differentiation, and neuroprotection. Highlighting the potential health significance of DHEA and DHEAS in humans, serum concentrations decrease steadily with age, with lowest concentrations present at the time many diseases of aging and neurodegeneration become apparent.
Changes in blood Cortisol compared to placebo.
Cortisol is a steroid hormone that is produced by the adrenal glands which sit on top of each kidney. When released into the bloodstream, cortisol can act on many different parts of the body and can help: body respond to stress or danger increase your body's metabolism of glucose control your blood pressure reduce inflammation. Cortisol is also needed for the fight or flight response which is a healthy, natural response to perceived threats. The amount of cortisol produced is highly regulated by your body to ensure the balance is correct.
Changes in blood High sensitivity CRP (hs CRP) compared to placebo.
High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death among healthy individuals with no history of cardiovascular disease, and recurrent events and death in patients with acute or stable coronary syndromes.
Improvements and differences compared to placebo on oxidative, inflammation, and stress biomarkers.
Analyses on inflammatory and anxiety measures cytokines including IL-2, IL-6, IL-10, IL-1beta, TNF-alpha, and BDNF will be performed by ELISA tool following the suppliers' protocol (eBioscience, Boston, MA).
Changes zonulin and calprotectin in fecal sample compared to placebo.
The composition of the gut microbiome from stool sample will be examined by Illumina MiSeq Platform. Fecal sample will be washed and prepared with sterile PBS. All samples will be prepared according to the manufacturer's guidelines. Fecal DNA on the V3-V4 regions will be amplified by16s amplicon PCR primers. An online bioinformatics database will be used for the identifications of bacteria and quality filtering.
Full Information
NCT ID
NCT05964231
First Posted
July 17, 2023
Last Updated
August 27, 2023
Sponsor
Mackay Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05964231
Brief Title
The Intervention of Psychobiotics in Patients With Anxiety Disorders
Official Title
A Double-blind Randomized Controlled Trial Investigating Associations of Microbiota, Serum Total Antioxidant Capacity and Sleep or Psychiatric Symptoms Before and After the Intake of Psychobiotic Lactobacillus Paracasei
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2023 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
July 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mackay Memorial Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The investigators designed this double blind randomized controlled study and will recruit 120 patients 20 to 65 years old, with DSM-5 generalized anxiety disorder or unspecified anxiety disorder. After clinical symptoms and psychological evaluation and blood sampling, a semi-structural interview delivered by a psychiatrist will be established to confirm the DSM-5 diagnosis. The participants will be randomly assigned to the Lactobacillus paracasei PS23 psychotropic probiotic or placebo group. Blood and stool samples will be obtained after consent. The samples will be tested for biochemistry, inflammation index, cytokines, intestinal osmotic pressure, or gut permeability, and a Fitbit fitness watch will be given to measure changes in sleep.
Detailed Description
This study aimed to recruit 120 subjects that meet the following inclusion criteria after the approval of the IRB. Those agreed to participate and signed the informed consent will be randomly divided into two groups of the Lactobacillus paracasei PS23 psychobiotics capsule and the placebo. Each group aims to recruit 60 people. The power analysis was conducted using effect size for outcomes of improvements in anxiety from previous studies. Based on a power of 80% and assuming a 30% dropout rate and an alpha level of 0.05, a sample of 120 participants (60 per group) will be required. All results will be analyzed using an intent-to-treat analysis based on treatment assignment, regardless of completion or not.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety Disorders
Keywords
anxiety, microbiota, psychobiotics
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Heat-treated PS23
Arm Type
Experimental
Arm Description
Lactobacillus paracasei PS23 heat-treated
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
microcrystalline cellulose
Intervention Type
Dietary Supplement
Intervention Name(s)
Heat-treated PS23
Intervention Description
Lactobacillus paracasei PS23 heat-treated, 2caps daily use
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
microcrystalline cellulose, 2caps daily use
Primary Outcome Measure Information:
Title
Changes from the HAM-A compared to placebo.
Description
Hamilton Anxiety Scale(HAM-A) score changes downwards ≥ 20% indicate significant improvement.
Time Frame
change from baseline score at 8 weeks
Secondary Outcome Measure Information:
Title
Differences in the Generalized Anxiety Disorder 7-item (GAD-7) compared to placebo.
Description
The GAD-7 is a easy to perform initial screening tool for generalized anxiety disorder, When screening for anxiety disorders, a score of 8 or greater represents a reasonable cut-point for identifying probable cases of generalized anxiety disorder;Using a cut-off of 8 the GAD-7 has a sensitivity of 92% and specificity of 76% for diagnosis generalized anxiety disorder.
Time Frame
change from baseline score at 8 weeks
Title
Differences in the State and Trait Anxiety Index (STAI) compared to placebo.
Description
The STAI measures levels of anxiety in the current 'state' or from the 'trait'. Good reliability (0.86~0.95) and sensitivity (0.85) were found and the higher the scores, the severe the levels of anxiety.
Time Frame
change from baseline score at 8 weeks
Title
Differences in Insomnia Severity index (ISI) compared to placebo.
Description
The ISI is a brief instrument that was designed to assess the severity of both nighttime and daytime components of insomnia.
Time Frame
change from baseline score at 8 weeks
Title
Differences in The Quality of Life, Enjoyment, and Satisfaction Questionnaire-16 (QLESQ-16) compared to placebo.
Description
The QLESQ-16 is a valid, reliable self-report instrument for assessing quality of life.
Time Frame
change from baseline score at 8 weeks
Title
Differences in the The Profile of Mood States (POMS) compared to placebo.
Description
The POMS is a psychological rating scale used to assess transient, distinct mood states.
Time Frame
change from baseline score at 8 weeks
Title
Differences in Visual Analogue Scale-GI (VAS-GI) compared to placebo.
Description
VAS consists of a line, 10 cm in length. Individuals point to or mark a spot on the line where they feel indicates their current their emotion, fatigue level and sleep quality. The score of emotion level is from 0cm (very nervous) to 10 cm (very relaxing). The score of fatigue level is from 0 cm (very energetic) to 10 cm (very sleepy). The score of sleep quality is from 0 cm (poor) to 10 cm (sleep well). The maximum total score is 100% (equal 10cm).
Time Frame
change from baseline score at 8 weeks
Title
Changes in blood TAC (Total Antioxidant Capacity) before and after consumption of probiotics
Description
TAC is the biomarker for Oxidative stress.
Time Frame
change from baseline score at 8 weeks
Title
Changes in blood DHEA-S (Dehydroepiandrosterone sulfate) compared to placebo.
Description
DHEA-S is the biomarker for anti-aging，among the neuroactive steroids, dehydroepiandrosterone (3b-hydroxyandrost-5-ene-17-one, [DHEA]) and its sulfated metabolite DHEA sulfate (DHEAS) have been shown to be potent modulators of neural function, including neurogenesis, neuronal growth and differentiation, and neuroprotection. Highlighting the potential health significance of DHEA and DHEAS in humans, serum concentrations decrease steadily with age, with lowest concentrations present at the time many diseases of aging and neurodegeneration become apparent.
Time Frame
change from baseline score at 8 weeks
Title
Changes in blood Cortisol compared to placebo.
Description
Cortisol is a steroid hormone that is produced by the adrenal glands which sit on top of each kidney. When released into the bloodstream, cortisol can act on many different parts of the body and can help: body respond to stress or danger increase your body's metabolism of glucose control your blood pressure reduce inflammation. Cortisol is also needed for the fight or flight response which is a healthy, natural response to perceived threats. The amount of cortisol produced is highly regulated by your body to ensure the balance is correct.
Time Frame
change from baseline score at 8 weeks
Title
Changes in blood High sensitivity CRP (hs CRP) compared to placebo.
Description
High-sensitivity C-reactive protein (hsCRP) is a marker of inflammation that predicts incident myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death among healthy individuals with no history of cardiovascular disease, and recurrent events and death in patients with acute or stable coronary syndromes.
Time Frame
change from baseline score at 8 weeks
Title
Improvements and differences compared to placebo on oxidative, inflammation, and stress biomarkers.
Description
Analyses on inflammatory and anxiety measures cytokines including IL-2, IL-6, IL-10, IL-1beta, TNF-alpha, and BDNF will be performed by ELISA tool following the suppliers' protocol (eBioscience, Boston, MA).
Time Frame
change from baseline score at 8 weeks
Title
Changes zonulin and calprotectin in fecal sample compared to placebo.
Description
The composition of the gut microbiome from stool sample will be examined by Illumina MiSeq Platform. Fecal sample will be washed and prepared with sterile PBS. All samples will be prepared according to the manufacturer's guidelines. Fecal DNA on the V3-V4 regions will be amplified by16s amplicon PCR primers. An online bioinformatics database will be used for the identifications of bacteria and quality filtering.
Time Frame
change from baseline score at 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 20~65 years old
Patients perceived that they had anxiety-related complaints, or with any type of anxiety disorders of adjustment disorders referred from the Departments of Psychiatry, Neurology, Internal Medicine, and Family Medicine in Mackay Memorial Hospital.
Adult GAD-7 ≥ 8 points (to screen for generalized anxiety disorder) or a DSM-5 diagnosis of generalized anxiety disorder (F41.1) or unspecified anxiety disorder (F41.9)
Those who are currently under the treatment of selective serotonin reuptake inhibitors (SSRI) will only be included if their SSRI treatment has been stable or has not been changed for 4 weeks.
Exclusion Criteria:
Have taken antibiotics or are receiving antibiotic treatment within one month.
Have used probiotic products in powder, capsule or tablet form within two weeks (excluding yogurt, Yakult and other related foods).
Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy).
Past or current patients with inflammatory bowel disease.
Those with a history of cancer.
Those who are allergic to lactic acid bacteria products.
Patients with severe depression (Patient Health Questionnaire-9 (PHQ-9) ≧ 20 points), or possible neurocognitive impairments (Mini-Mental States Examination (MMSE)<20), or those that had suicidal ideation noted on item 9 from PHQ-9.
Patients with chronic psychiatric diseases who are currently taking drugs to treat acute diseases, organic brain diseases, or newly diagnosed or changed drugs within three months.
Those who are receiving parenteral nutrition.
Those who are evaluated by the principal investigator to be unsuitable to participate in the research.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shu-I Wu, PhD
Phone
+886-975835215
Email
shuiwu624@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shu-I Wu, PhD
Organizational Affiliation
Mackay Memorial Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mackay Memorial Hospital
City
Taipei
ZIP/Postal Code
10448
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shu-I Wu, PhD
Phone
+886-975835215
Email
shuiwu624@gmail.com
First Name & Middle Initial & Last Name & Degree
Wan-Lin Chen, Bacholar
Phone
+886-918830146
Email
fatty09222002@gmail.com
12. IPD Sharing Statement
Learn more about this trial
The Intervention of Psychobiotics in Patients With Anxiety Disorders
We'll reach out to this number within 24 hrs